西妥昔单抗治疗头颈鳞状细胞癌的研究进展  

Research progress of cetuximab in the treatment of head and neck squamous cell carcinoma

作　　者：刘雨植 刘宏伟[2] LIU Yuzhi;LIU Hongwei(The First Clinical College,Liaoning University of Traditional Chinese Medicine,Shenyang 110847,China;Department of Thyroid,Head and Neck Surgery,Liaoning Cancer Hospital)

机构地区：[1]辽宁中医药大学第一临床学院,辽宁沈阳110847 [2]辽宁省肿瘤医院甲状腺头颈外科

出　　处：《沈阳医学院学报》2024年第2期193-199,共7页Journal of Shenyang Medical College

基　　金：辽宁省自然科学基金项目(No.20180550376)。

摘　　要：头颈鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是头颈肿瘤中最常见的一种类型,其预后不佳,患者生活质量差。近年来随着靶向治疗相关研究飞速发展,西妥昔单抗被食品药品监督管理局(FDA)批准治疗HNSCC的分子靶向药物被广泛用于临床。针对局部晚期和复发/远处转移型HNSCC,不论是西妥昔单抗与放疗、化疗、同期放化疗联合,还是诱导化疗后联合放疗,都展现出巨大优势。HNSCC的治疗现已进入免疫时代,多项临床试验数据表明西妥昔单抗联合免疫治疗或新型靶向药物对HNSCC也有显著疗效,未来需要学者们对免疫治疗更深入探索,为HNSCC患者提供更优选择。本文将对西妥昔单抗的作用机制及其在HNSCC治疗的研究进展做以综述。Head and neck squamous cell carcinoma(HNSCC)is the most common type of head and neck cancer,with poor prognosis and poor quality of life.In recent years,with the rapid development of targeted therapy,cetuximab has been widely used in clinical practice as the molecular targeted drug approved by the Food and Drug Administration(FDA)for the treatment of HNSCC.For locally advanced and recurrent/distant metastatic HNSCC,cetuximab combined with radiotherapy,chemotherapy,concurrent chemoradiotherapy,or combined radiotherapy after induction chemotherapy have shown great advantages.The treatment of HNSCC has now entered the era of immunity.Several clinical trials data have shown that cetuximab combined with immunotherapy or new targeted drugs have significant effects on HNSCC.In the future,scholars need to further explore immunotherapy to provide better choices for patients with HNSCC.This article reviews the mechanism of action of cetuximab and its research progress in the treatment of HNSCC.

关 键 词：西妥昔单抗 头颈鳞状细胞癌 局部晚期头颈部鳞癌 复发/转移头颈鳞癌 

分 类 号：R739.91[医药卫生—肿瘤]